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Diagnosis and management begins in the emergency department (ED) for the vast majority of patients hospitalized with acute heart failure (AHF). Unfortunately, the evidence base for ED management is limited. 1, 2 This lack of evidence, combined with the heterogeneity of the AHF patient population, results in tremendous variability in clinical practice. The potential impact of ED management is significant, as diagnostic delay or sub-optimal treatment may have significant downstream consequences. Perhaps the costliest ED management decision is deciding who does or does not require hospitalization, the most expensive resource in healthcare. 3, 4 As epidemiology and pathophysiology of AHF are covered elsewhere, this review focuses on initial ED management.
Stabilization
Occasionally, patients with possible AHF present in extremis or near respiratory failure. In these instances, the diagnostic work up and management occur in parallel. Importantly, the precipitating cause of the patient's dramatic presentation must be simultaneously identified and treated. Arrhythmias, infection, and acute coronary syndromes are just a few potential precipitants. The classical teaching of ensuring "Airway, Breathing, and Circulation" first is worth reiterating.
Obtunded patients with severe respiratory failure will likely require endotracheal intubation and mechanical ventilation. 5 For patients with respiratory distress who are awake and cooperative, early initiation of non-invasive positive pressure ventilation (NIPPV)
significantly decreases mortality and need for intubation. 6 NIPPV can be instituted even if the diagnosis of AHF is in doubt, as evidence suggests benefit even in undifferentiated severe
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7 dyspnea. 7 The increased intra-thoracic pressure from NIPPV may decrease blood pressure (BP), but this is uncommon clinically and more likely with endotracheal intubation. Once the patient has been stabilized, the focus turns to diagnosis.
Initial Diagnosis and Assessment
Fortunately, most AHF patients do not present in extremis. Establishing the diagnosis is the sine qua non of medicine, but is not always easy. It is worth noting the myriad of different patient complaints: Fatigue, dizziness, shortness of breath, chest pain, weakness, exercise intolerance, swelling, and weight gain are all symptoms prompting consideration of AHF as the cause.
The clinical presentation of AHF varies widely, ranging from mildly worsening heart failure, de novo or new onset HF, to overt cardiogenic shock, to hypertensive flash pulmonary edema. Despite the high prevalence of AHF in the ED setting, misdiagnosis occurs in 14-29% of patients [8] [9] [10] [11] . Heterogeneous pathophysiology and phenotypic expression, varied underlying causes and precipitants, and substantial co-morbid burden underlie the challenges of diagnosing this syndrome. Nevertheless, timely and accurate diagnosis of AHF is critical to preventing delays in treatment, which have been associated with increased risk of inpatient mortality and longer length of stay (LOS). [12] [13] [14] .
Unfortunately, no single historical variable, symptom, physical exam finding, biomarker, or imaging modality is sensitive enough to sufficiently exclude the diagnosis of AHF. Dyspnea is the most common symptom prompting patients with AHF to seek care 15 , and is most often due M A N U S C R I P T 16 . Jugular venous distension and the hepatojugular reflex are more specific, but are insensitive and dependent on the examiner. Despite knowledge that congestion is the primary underlying cause of patient signs and symptoms, measuring congestion with a high degree of intra and interobserver reliability remains challenging. 17, 18 Natriuretic peptides are the most useful biomarkers for excluding the diagnosis of AHF 19 . Cutoff points of 100 pg/mL and 300 pg/mL for brain natriuretic peptide (BNP) and Nterminal (NT)-proBNP, respectively, substantially reduce the post-test probability of AHF (LR-0.1) in patients presenting to the ED with dyspnea 16 . Very high BNP values are modestly helpful in ruling in AHF, but intermediate values (100-800 pg/mL for BNP) lack diagnostic specificity.
Likelihood ratios associated with even the most elevated NT-proBNP values only modestly favor the diagnosis of AHF 16 . The specificity of these biomarkers above proposed cutoff points are limited by renal dysfunction and advanced age 19 . Other conditions to consider in patients with modestly elevated BNP values are acute respiratory distress syndrome 20 , pulmonary embolism 21, 22 , pulmonary hypertension 23 , and valvular heart disease 24 . While natriuretic peptides provide additive diagnostic value beyond clinical and historical variables [25] [26] [27] , several
studies have failed to demonstrate differences in patient-centered clinical outcomes beyond hospital LOS 28, 29 with the addition of diagnostic BNP testing.
In addition to a basic metabolic profile and complete blood count, troponin testing should be considered in AHF patients. Occasionally, troponin testing may uncover occult acute coronary syndrome (ACS), an important precipitant of AHF. 30, 31 Importantly, an elevated troponin does not rule in ACS, as many AHF patients may have troponin release. 32 With the recent approval in the US of higher sensitivity assays, a greater proportion of AHF patients will likely be identified with "abnormal" troponin values. 33 Troponins also add prognostic information, 30 but should not be considered a diagnostic test to rule in or out AHF. However,
higher sensitivity assays may demonstrate troponin release as an integral part of the AHF syndrome; one recent study demonstrated 98% of AHF patients have measurable troponin, with 81% above the 99 th percentile. 34 Both BNP and troponin are recommended in guidelines for the assessment and risk-stratification of the AHF patient. 35, 36 Given the limitations of laboratory testing in isolation, imaging plays a significant role in the diagnostic approach to AHF. The chest radiograph is considered a key component of the diagnostic workup. Chest radiography can identify vascular engorgement, hilar redistribution, interstitial edema, and alveolar edema as well as alternative causes of dyspnea 37 . While highly specific for AHF, these radiographic findings are poorly sensitive. 25, 38, 39 One series found that cardiomegaly alone had moderate sensitivity (79%) and specificity (80%). 25 Lung ultrasound has emerged as a useful point-of-care tool for identifying pulmonary edema and diagnosing AHF. 16 . The extent of pulmonary edema can also be semi-quantitatively measured by the sum of the number of Blines with high inter-rater reliability [42] [43] [44] . B-line severity has been shown to correlate with other measures of pulmonary congestion 45 and with the severity of AHF 46, 47 . The ESC HF guidelines now includes lung ultrasound as a recommended diagnostic test to confirm pulmonary congestion 37 .
Point-of-care ultrasound -determined estimates of intravascular volume and right atrial pressures can be made by measuring the diameter of the inferior vena cava (IVC) and percentage change in IVC diameter during the respiratory cycle. An IVC diameter that fails to substantially decrease with inspiration is considered to have a low collapsibility (or caval) index (IVC-CI), reflecting volume overload and high RAP. The diagnostic performance of different cutoff values for IVC collapsibility index, ranging from 20%-50% have been tested in dyspneic patients presenting to the ED [48] [49] [50] [51] . Sensitivities of 80% or greater were achieved in studies that used an IVC-CI cutoff of 33% or greater [49] [50] [51] . Specificities associated with these cut-offs ranged from 81%-87%. Alternative causes of a plethoric IVC include tricuspid regurgitation, pulmonary embolism, pulmonary hypertension, and right ventricular infarction.
Echocardiography is integral to the diagnostic workup of HF. While formal echocardiography is rarely available rapidly in the ED, focused cardiac ultrasound in the hands 54 . Acquisition and interpretation of mitral inflow and tissue Doppler data is currently beyond the scope of ED physicians who lack formal fellowship training. Diagnostic approaches that integrate lung, cardiac, and IVC assessments increase the specificity of diagnosing AHF in the ED beyond clinical gestalt, biomarkers, and lung ultrasound alone 48, 50, 55 . Further research is needed to help delineate the role of focused cardiac ultrasound in the workup of AHF and how different sonographic assessments can be incorporated into diagnostic algorithms.
Importantly, point of care US does not replace formal echocardiography.
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Initial Classification
As an initial guide, we recommend grouping patients with suspected AHF by systolic BP (SBP). 58, 59 As evidenced by registries, SBP is often high (>140mmHg) at the time of presentation. 60 We recommend using cutpoints of > 140mmHg, 100-140 mmHg, and < 100 mmHg to guide initial selection of pharmacologic therapy. 58, 59 While there is considerable overlap, simple categorization aids the busy clinician. As such, it is reasonable to assume the predominant pathophysiologic derangement in a patient based on presenting SBP. Notably, not all patients present with total volume overload; the prototypical example is the flash pulmonary edema patient. [61] [62] [63] Such patients have also been described as 'vascular failure' or 'volume redistribution' patients. [64] [65] [66] These patients most commonly present with elevated SBP. Of note, the latest ESC HF guidelines also support dividing patients based on 'cardiac' (fluid overload predominates) vs. 'vascular' (hypertension predominates) phenotypes.
1
Initial Therapy
At the present time, no AHF therapy receives a Level I, Class A recommendation from guidelines, 1,2 highlighting the lack of robust evidence from randomized studies. Therapies used today are largely the same as those employed 4 decades ago (Table 2) . Rotating tourniquets and phlebotomy are no longer used; whether this represents a major advance is debatable.
Importantly, lack of high quality evidence from robust, randomized controlled trials does not equate with ineffectiveness in achieving symptom relief, hemodynamic improvement, and decongestion; all important targets of therapies. Shock due solely to worsening HF rarely occurs relative to other types of AHF. 68 Given its relatively uncommon presentation combined with the complexity of these patients' underlying pathophysiology, precipitant, cardiac structure, function, and resultant hemodynamic status, management can be challenging. Patients with advanced HF may present with alarmingly low SBP. This may, in fact, reflect their baseline SBP. Even when resuscitating shock, a common mistake is attempting to normalize SBP and HR to values seen in those with baseline normal cardiac structure and function. However, for patients with severely reduced EF, a 'normal' SBP may be unattainable, and tachycardia may be the key contributor to cardiac output.
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For patients with low SBP, administering a fluid bolus is nearly a reflexive action.
But in the setting of hypoperfusion secondary to heart failure rather than hypovolemia, this may result in worsening pulmonary edema. On the other hand, infection and overdiuresis are common precipitants that may respond quite well to fluid. At the bedside, assessing volume status is challenging, especially in patients with advanced HF. As noted above, ultrasound may be useful, but response to initial treatment will often be the best guide to
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15 subsequent management. Although rarely applied in the ED setting due to concerns of precipitating circulatory failure, AHF patients with low SBP who are congested may require decongestive therapies. Optimizing volume status through diuresis and vasodilation may lead to significant clinical improvement. In some refractory cases, inotropes and vasopressors are required to augment cardiac output and blood pressure. Table 3 shows commonly used inotropes and vasopressors. Although inotropes and vasodilators improve hemodynamics, to date, none are associated with better clinical outcomes. In fact, available inotropes have been associated with harm, though the evidence base is small and inconsistent. [69] [70] [71] [72] In terms of vasopressors, there is a paucity of robust data to strongly recommend one vasopressor over another. Subgroup analysis from a large randomized trial found increased mortality in patients with cardiogenic shock who were randomized to dopamine compared with those randomized to norepinephrine. 73 Table 3 Initial 
Inotropes and Vasopressors
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The Hypertensive Patient
Approximately half of patients admitted with AHF present with hypertension (SBP ≥ 140 mmHg). 60, 68 In general, these patients tend to be older, have preserved EF, 60 and present with a more acute onset of symptoms, often less than 24 hours. Pulmonary edema in such patients is more likely to be caused by vascular redistribution than by hypervolemia. As such, vasodilators are the mainstay of treatment.
Of the guideline-recommended vasodilator options [nitroglycerin (NTG), nitroprusside,
or nesiritide], we recommend NTG as first line. 74 Clinicians and nurses are familiar with NTG; it can be administered rapidly via sublingual and intravenous routes, and it's inexpensive. Bolus doses of up to 2-3 mg are well tolerated and effective, though many clinicians are reluctant to
give such large doses. 75, 76 Anecdotally, NTG as an IV drip is often withheld due to the requirement for an intensive care unit (ICU)bed. However, the rapid onset/offset of NTG make it an ideal titratable drug to initiate before transitioning to topical NTG or alternative therapies.
Nitroprusside and nesiritide are alternatives to NTG. As with NTG, neither nitroprusside nor nesiritide has been shown to decrease mortality or morbidity in AHF. 77 However, both are effective vasodilators, with nitroprusside being the more potent. While NTG predominantly acts on the venous circulation until at higher doses, nitroprusside acts rapidly on both the arterial and venous circulation. It may precipitously lower BP; thus careful monitoring is required.
Nesiritide is one of the most well studied vasodilators in terms of large randomized controlled trials. After initial concerns regarding safety, a large randomized, controlled trial (ASCEND-HF; n= 7,141) found no relative benefit or harm associated with nesiritide in terms of mortality,
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17 hospital readmission, or dyspnea. 78 It may be a reasonable option if a vasodilator is desired but ICU beds are unavailable.
Despite the lack of compelling evidence supporting acute angiotensin converting enzyme inhibitor (ACEI) use in the ED, these agents are sufficiently used in the setting of AHF to be mentioned in the American College of Emergency Physicians 79 . A common misperception:
the benefit of ACEI in chronic HF with reduced EF extends to the acute setting. Lack of evidence does not equal a bad therapy; only that sufficiently powered, well-designed trials have not yet been performed.
Morphine's historic use in AHF continues today. Retrospective observational data suggests an increased risk of death in patients treated with morphine for AHF. 80 As it offers no defined benefit, we recommend against routine morphine use in AHF.
The Normotensive Patient (SBP 100-140mmHg)
AHF patients presenting with SBP ranging from 100-140mmHg rarely arrive to the ED in extremis. 60 The prototypical patient reports an indolent course over days or even weeks, and may report significant weight gain. Decongestion with intravenous (IV) loop diuretics is the primary therapy. Bolus or continuous infusion diuretic administration makes no difference. 81 A randomized trial comparing IV doses of the patient's standard oral dose to larger IV doses (2.5
times the standard oral dose) found that larger doses resulted in more diuresis and marginally better dyspnea over the first 72 hours, but also increased the likelihood of creatinine elevation. 81 In addition to diuretic therapy, low-dose vasodilators should be considered in normotensive patients.
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A Hospitalist's Perspective in Brief:
From the hospitalist perspective, whether so many AHF patients warrant admission is debatable. 82 and ESC guidelines, though large randomized controlled trials have yet to be performed (and it is doubtful they ever will be). Given the absence of other therapies to readily decongest patients, why IV diuretics are withheld or underdosed appears perplexing. Although retrospective studies suggest harm associated with early aggressive IV loop diuretic use, no prospective evidence supports this hypothesis.￼ 84, 85 . Withholding IV diuretics in the ED may be perceived by the inpatient teams as delaying patient care.
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If diuretics are given in the ED, they are often underdosed. By their very mechanism of action, 86 loop diuretics must be secreted via active transport in the proximal tubules of the kidney.
Rather than minimize doses, especially in patients with impaired renal function, higher doses are required to reach the dose-response threshold.
86
Disposition and Outcomes
Contrary to commonly held belief, most patients who visit the ED are sent home; only 9.3% of the annual 130 million ED visits in the US result in hospitalization. However, nearly all ED patients with AHF are hospitalized. From 2006 to 2011, the annual US hospitalization rate for AHF patients in the ED has consistently been around 85%. 87 Given financial penalties tied to excess re-hospitalization, this admission rate warrants scrutiny.
Administrative data analyses suggest up to 50% of patients with AHF could be discharged or observed briefly and released. 88 AHF is a progressive illness and the short-term prognosis following hospitalization is unacceptably poor. This makes the concept of a low-risk AHF patient difficult for the emergency physician to embrace. Yet within the spectrum of risk, some are lower than others. Identifying patients safe to be sent home from the ED remains challenging, as the majority of risk-stratification work in AHF focuses on defining and characterizing high risk in-patients, making extrapolation to the ED setting challenging. 89 While some risk instruments, such as the AHF Index, EMHRG, STRATIFY, or the Ottawa Heart Failure Index are promising, [90] [91] [92] none have gained widespread acceptance, either due to the need for further validation, differences in patient populations, or limited information on outcomes for
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The absence of high risk features (i.e. low BP, high BNP levels, worsening renal function, elevated troponin, and hyponatremia) does not equal no risk, 89, 94, 95 but it does equate to lower risk. In the future, absence of myocardial injury by high sensitivity troponin assays may help identify low risk patients. 96 As risk-stratification improves, appropriate selection of patients for treatment in observation or short-stay units in AHF may become easier. 97, 98 These units may provide more time to risk stratify patients, gauge response to therapy, provide education, engage case management and social work as needed, reconcile medications, and facilitate close follow up. These tasks are often challenging to complete during a brief ED stay. Furthermore,
given the reluctance to discharge lower-risk AHF patients from the ED, the use of observation medicine as a 'bridge' may be more clinically feasible and acceptable to ED physicians. 3, 94 For higher risk patients, hospitalization may offer benefit to improve symptoms, optimize volume status, and ensure initiation of guideline directed chronic medical therapy.
AHF pharmacologic therapies, on their own, have not been proven to affect post-discharge outcomes. 2 However, hospitalization may help higher risk patients achieve symptomatic relief, euvolemia/complete decongestion, and medical optimization. Patients with new onset or de novo HF should also be admitted, as potentially reversible or modifiable causes may be identified. These patients will also need education about self-managing their new chronic illness. Overall however, indiscriminate admission is unlikely to translate into patient-centered benefit or justifiable cost. As mentioned previously, identifying who can be safely observed or discharged from the ED remains an unmet need.
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Conclusion:
The ED management of AHF centers around diagnosis, stabilization, identification of the precipitant of AHF, initial treatment, and risk-stratification. We recommend initial ED treatment be guided by presenting phenotype but treatment largely centers around diuretics and vasodilators. Although currently available therapies improve symptoms, none definitively improve outcomes. Identification of life saving therapies for the early treatment of AHF remains an unmet need, though whether a short-term treatment can influence longer term post-discharge outcomes remains unclear. As US EDs continue to admit nearly all AHF patients, identifying appropriate low-risk patients for discharge and close follow-up would result in tremendous value to the health care system.
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